Literature DB >> 28234156

Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: Clinical outcome and predictive factors of recurrence.

Rafaela Veloso-Teles, Rui Cerejeira.   

Abstract

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly prevalent disease of the nasal cavity and paranasal sinus, but its exact etiology is still unclear and remains a difficult-to-treat condition. HYPOTHESIS: Endoscopic sinus surgery (ESS) is an effective treatment for medically recalcitrant CRSwNP. There are independent variables that can predict surgical outcomes in patients with CRSwNP.
OBJECTIVES: To evaluate ESS efficacy in CRSwNP treatment and to establish prognostic factors for disease recurrence.
METHODS: Eighty-five patients with CRSwNP submitted to ESS, and a minimum follow-up of 9 months was selected. Patient demographics, occupational organic exposure (e.g., cotton, fuel gas, wood dust) and inorganic dust exposure (e.g., bleach, metals, cement), comorbidities, previous nasal surgeries, pre- and postoperative symptoms, ear, nose and throat examination findings, computed tomography results, and medical and surgical treatment information were collected from medical records. Statistical analysis was performed.
RESULTS: All rhinologic symptoms improved after surgery, in a statistically significant way, with the best recovery rate for nasal obstruction and the worst for hyposmia. The major and minor complications rates were 1.2 and 15.3%, respectively. Disease recurrence occurred in 31% of the patient, but only 7% required surgical reintervention. Multivariate logistic regression analysis identified occupational dust exposure (p = 0.001) and non-immunoglobulin E (IgE) mediated asthma (p = 0.012) as independent predictive variables in CRSwNP recurrence, unlike the other tested variables: age, sex, IgE-mediated asthma, allergic rhinitis, smoking habits, nasal polyps endoscopic grade, Lund-Mackay score, and postoperative topical corticoid use. The adjusted logistic model presented a good discriminatory capacity with a receiver operating characteristic area under the curve of 0.82 (95% confidence interval, 0.73-0.91; p < 0.001).
CONCLUSION: ESS proved to be an effective treatment in CRSwNP but with a considerable rate of recurrence. These results indicated an important correlation of occupational dust exposure and non-IgE-mediated asthma with disease recurrence.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28234156     DOI: 10.2500/ajra.2017.31.4402

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  15 in total

1.  Aberrant expression of miR-663 and transforming growth factor-β1 in nasal polyposis in children.

Authors:  Hailing Yu; Jianbao Ju; Jingdong Liu; Da Li
Journal:  Exp Ther Med       Date:  2018-03-06       Impact factor: 2.447

Review 2.  The Role of Epigenetics in the Chronic Sinusitis with Nasal Polyp.

Authors:  Tiancong Liu; Yang Sun; Weiliang Bai
Journal:  Curr Allergy Asthma Rep       Date:  2020-11-24       Impact factor: 4.806

3.  Efficacy and safety of delivery of topical medication on to the frontal sinus at different head positions after frontal sinusotomy.

Authors:  Yu-Xiao Wu; Min Wang; Hui Li; Zhi-Min Xing; Mu-Han Shi; Shi-En Huang; Yan Liu; Cong-Li Geng
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-13       Impact factor: 2.503

4.  Advanced age adversely affects chronic rhinosinusitis surgical outcomes.

Authors:  Kristen L Yancey; Anne S Lowery; Rakesh K Chandra; Naweed I Chowdhury; Justin H Turner
Journal:  Int Forum Allergy Rhinol       Date:  2019-08-27       Impact factor: 3.858

5.  Construction and analysis of a ceRNA network and patterns of immune infiltration in chronic rhinosinusitis with nasal polyps: based on data mining and experimental verification.

Authors:  Jing-Cai Chen; Qi-Long Xing; Hui-Wen Yang; Fan Yang; Yao Luo; Wei-Jia Kong; Yan-Jun Wang
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

Review 6.  Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis.

Authors:  Zheng Liu; Jianjun Chen; Lei Cheng; Huabin Li; Shixi Liu; Hongfei Lou; Jianbo Shi; Ying Sun; Dehui Wang; Chengshuo Wang; Xiangdong Wang; Yongxiang Wei; Weiping Wen; Pingchang Yang; Qintai Yang; Gehua Zhang; Yuan Zhang; Changqing Zhao; Dongdong Zhu; Li Zhu; Fenghong Chen; Yi Dong; Qingling Fu; Jingyun Li; Yanqing Li; Chengyao Liu; Feng Liu; Meiping Lu; Yifan Meng; Jichao Sha; Wenyu She; Lili Shi; Kuiji Wang; Jinmei Xue; Luoying Yang; Min Yin; Lichuan Zhang; Ming Zheng; Bing Zhou; Luo Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2020-03       Impact factor: 5.764

7.  Risk Model Establishment of Endoscopic Sinus Surgery for Patients with Chronic Rhinosinusitis: a Multicenter Study in Korea.

Authors:  Jin-Young Min; Yong Min Kim; Dae Woo Kim; Jeong-Whun Kim; Jin Kook Kim; Ji-Hun Mo; Jae-Min Shin; Kyu-Sup Cho; Sanggyu Kwak; Seung-Heon Shin
Journal:  J Korean Med Sci       Date:  2021-10-18       Impact factor: 2.153

8.  Assessing Cut-off Points of Eosinophils, Nasal Polyp, and Lund-Mackay Scores to Predict Surgery in Nasal Polyposis: A Real-World Study.

Authors:  P Virkkula; E Penttilä; S I Vento; J Myller; A Koskinen; S Hammarén-Malmi; A Laulajainen-Hongisto; M Hytönen; M Lilja; J Numminen; S Sillanpää; J Sahlman; S Toppila-Salmi
Journal:  Allergy Rhinol (Providence)       Date:  2020-10-19

Review 9.  Eosinophils from Physiology to Disease: A Comprehensive Review.

Authors:  Giuseppe A Ramirez; Mona-Rita Yacoub; Marco Ripa; Daniele Mannina; Adriana Cariddi; Nicoletta Saporiti; Fabio Ciceri; Antonella Castagna; Giselda Colombo; Lorenzo Dagna
Journal:  Biomed Res Int       Date:  2018-01-28       Impact factor: 3.411

10.  Chlorpheniramine attenuates histamine-mediated aquaporin 5 downregulation in human nasal epithelial cells via suppression of NF-κB activation.

Authors:  Yung-Lung Chang; Chun-Shu Lin; Hsing-Won Wang; Kai Ren Jian; Shao-Cheng Liu
Journal:  Int J Med Sci       Date:  2017-09-30       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.